Gut Microbiota Reconstruction in the Treatment of Irritable Bowel Syndrome With Predominant Diarrhea
Status:
Unknown status
Trial end date:
2020-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy as well as safety of rifaximin combined
fecal microbiota transplantation(Gut microbiota reconstruction) in the treatment of IBS-D.